Urinary 6-keto-PGF1 alpha level in patients with childhood leukemia/lymphoma; a possible indicator of vascular damage.
To determine the effect of anti-neoplastic chemotherapy on the vascular system(s) of children with leukemia/lymphoma, urinary excretion of 6-keto-PGF1 alpha was measured by radioimmunoassay (RIA). In 4 patients receiving therapy, 6-keto-PGF1 alpha increased to a mean of 148 (range; 126-170)% during therapy, then returned to pre-treatment level 3-5 days later. In 18 long-term survivors who had completed therapy, 6-keto-PGF1 alpha was determined to be a mean of 275 (range; 52-905) ng/g creatinine, and in the healthy control children the mean was 146 (range; 71-348) ng/g creatinine. These results were contrary to our hypothesis that chemotherapy might cause a decreased synthesis of PGI2, a precursor of 6-keto-PGF1 alpha, and suggest that increased urinary 6-keto-PGF1 alpha reflects a vascular response to acute exposure to chemotherapeutic drugs and possible vascular damage due to long-term intensive chemotherapy in pediatric patients with leukemia/lymphoma.
D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy / Q000652:urine*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000652:urine*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000652:urine*; D008297:Male; D011379:Prognosis; D011863:Radioimmunoassay; D012016:Reference Values
D015121:6-Ketoprostaglandin F1 alpha